Perrigo Announces the Launch of the AB Rated Generic Version of Transderm Scop® 1.5 mg

PRNewswire: July 31, 2017 – DUBLIN, Ireland – Perrigo Company plc (NYSE; TASE: PRGO) and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, today announced the prescription pharmaceutical launch of scopolamine 1.5 mg transdermal system patch, the AB rated generic equivalent to Transderm Scop® (scopolamine 1.5 mg).

Transderm Scop® (scopolamine 1.5 mg) transdermal system patch is an anticholinergic indicated for the prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia after surgery in adults. Annual market sales for the 12 months ending May 2017 were approximately $158 million.

Perrigo executive vice president and president Rx pharmaceuticals John Wesolowski stated, “I would like to thank the R&D and regulatory teams for their efforts to bring this difficult-to-manufacture product to market. This launch is another example of our ability to deliver complex generic products to patients at more affordable prices.”

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products® . Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization, and a world-class supply chain network. Perrigo is the world’s largest manufacturer of over-the-counter (OTC) healthcare products and supplier of infant formulas for the store-brand market. The company also is a leading provider of branded OTC products throughout Europe and the United States, as well as a leading producer of “extended topical” prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel, and China. Visit Perrigo online at www.perrigo.com